1
|
Brands C, Morcock D, Estes J, Deleage C. Next-generation Viral RNA/DNA in situ Hybridization Applications in Human Immunodeficiency Virus/Simian Immunodeficiency Virus Research. J Vis Exp 2020. [PMID: 32628155 DOI: 10.3791/60318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
In situ hybridization is a powerful technique to identify specific RNA or DNA sequences within individual cells in tissue sections, providing important insights into physiological processes and disease pathogenesis. In situ hybridization (ISH) has been used for many years to assess the location of cells infected by viruses, but recently a next-generation ISH approach was developed with a unique probe design strategy that allows simultaneous signal amplification and background suppression to achieve single-molecule visualization while preserving tissue morphology. This next-generation ISH is based on an approach like branched PCR, but performed in situ and is more facile, sensitive, and reproducible than classical ISH methods or in situ PCR approaches in routinely detecting RNA or DNA in formalin-fixed paraffin embedded (FFPE) tissues. For the last several years our laboratory has been applying this ISH platform for the detection of human immunodeficiency (HIV) and simian immunodeficiency (SIV) viral RNA (vRNA) and/or viral DNA (vDNA) positive cells within a multitude of FFPE tissues. With this detailed technical manuscript, we would like to share our knowledge and advice with all individuals interested in using next-generation ISH in their research.
Collapse
Affiliation(s)
- Catherine Brands
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc
| | - David Morcock
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc
| | - Jacob Estes
- Vaccine and Gene Therapy Institute and Oregon National Primate Research Center (ONPRC), Oregon Health and Science University (OHSU)
| | - Claire Deleage
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc.;
| |
Collapse
|
2
|
Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, Hagen SI, Shoemaker R, Deleage C, Lucero C, Morcock D, Swanson T, Legasse AW, Axthelm MK, Hesselgesser J, Geleziunas R, Hirsch VM, Edlefsen PT, Piatak M, Estes JD, Lifson JD, Picker LJ. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 2015; 21:132-9. [PMID: 25599132 PMCID: PMC4320022 DOI: 10.1038/nm.3781] [Citation(s) in RCA: 391] [Impact Index Per Article: 43.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 11/30/2014] [Indexed: 12/17/2022]
Abstract
Chronic-phase HIV and simian immunodeficiency virus (SIV) replication is reduced by as much as 10,000-fold in elite controllers (ECs) compared with typical progressors (TPs), but sufficient viral replication persists in EC tissues to allow viral sequence evolution and induce excess immune activation. Here we show that productive SIV infection in rhesus monkey ECs, but not TPs, is markedly restricted to CD4(+) follicular helper T (TFH) cells, suggesting that these EC monkeys' highly effective SIV-specific CD8(+) T cells can effectively clear productive SIV infection from extrafollicular sites, but their relative exclusion from B cell follicles prevents their elimination of productively infected TFH cells. CD8(+) lymphocyte depletion in EC monkeys resulted in a dramatic re-distribution of productive SIV infection to non-TFH cells, with restriction of productive infection to TFH cells resuming upon CD8(+) T cell recovery. Thus, B cell follicles constitute 'sanctuaries' for persistent SIV replication in the presence of potent anti-viral CD8(+) T cell responses, potentially complicating efforts to cure HIV infection with therapeutic vaccination or T cell immunotherapy.
Collapse
Affiliation(s)
- Yoshinori Fukazawa
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Richard Lum
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Afam A Okoye
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Haesun Park
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Kenta Matsuda
- Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Jin Young Bae
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Shoko I Hagen
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Rebecca Shoemaker
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - Claire Deleage
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - Carissa Lucero
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - David Morcock
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - Tonya Swanson
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Alfred W Legasse
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | - Michael K Axthelm
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| | | | | | - Vanessa M Hirsch
- Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Paul T Edlefsen
- Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Michael Piatak
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - Jacob D Estes
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - Jeffrey D Lifson
- AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA
| | - Louis J Picker
- 1] Vaccine and Gene Therapy Institute, Oregon Health &Science University, Beaverton, Oregon, USA. [2] Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon, USA
| |
Collapse
|
3
|
Klatt N, Canary L, Vinton C, Morcock D, Estes J, Brenchley J. Rate of AIDS progression is associated with gastrointestinal dysfunction in SIV-infected pigtail macaques (P3045). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.55.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
During HIV/SIV infection, mucosal immune system dysfunction and systemic immune activation are associated with progression to AIDS, however it is unclear to what extent pre-existing gastrointestinal damage relates to disease progression after infection. Pigtail macaques (PTM) are an excellent model in which to assess mucosal dysfunction in relation to HIV/SIV pathogenesis, as the majority of these animals have high levels of gastrointestinal damage, immune activation, and microbial translocation prior to infection, and rapidly progress to AIDS upon SIV infection. Here we characterized the mucosal immune environment prior to and throughout SIV infection in 13 uninfected PTM and 9 SIV-infected PTM, of which 3 were slow progressors. This small subset of slow progressors had limited innate immune activation in mucosal tissues in the periphery, which was associated with a more intact colonic epithelial barrier. Furthermore, we found that pre-infection levels of microbial translocation, as measured by lipopolysaccharide binding protein (LBP), in PTM correlated with the rate of progression to AIDS. These data suggest that pre-existing levels of microbial translocation and gastrointestinal tract dysfunction may influence the rate of HIV disease progression.
Collapse
Affiliation(s)
- Nichole Klatt
- 2Deptartment of Pharmaceutics, University of Washington, Seattle, WA
- 1NIAID, LMM, NIH, Bethesda, MD
| | | | | | - David Morcock
- 3AIDS and Cancer and Virus Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Jacob Estes
- 3AIDS and Cancer and Virus Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD
| | | |
Collapse
|
4
|
Klatt NR, Harris LD, Vinton CL, Sung H, Briant JA, Tabb B, Morcock D, McGinty JW, Lifson JD, Lafont BA, Martin MA, Levine AD, Estes JD, Brenchley JM. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol 2010; 3:387-98. [PMID: 20357762 PMCID: PMC2891168 DOI: 10.1038/mi.2010.14] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Pigtail macaques (PTMs) rapidly progress to AIDS after simian immunodeficiency virus (SIV) infection. Given the strong association between human immunodeficiency virus (HIV) and SIV disease progression and microbial translocation and immune activation, we assessed whether high basal levels of immune activation and microbial translocation exist in PTMs. We found that before SIV infection, PTMs had high levels of microbial translocation that correlated with significant damage to the structural barrier of the gastrointestinal tract. Moreover, this increased microbial translocation correlated with high levels of immune activation and was associated with high frequencies of interleukin-17-producing T cells. These data highlight the relationship among mucosal damage, microbial translocation and systemic immune activation in the absence of SIV replication, and underscore the importance of microbial translocation in the rapid course of disease progression in SIV-infected PTMs. Furthermore, these data suggest that PTM may be an ideal model to study therapeutic interventions aimed at decreasing microbial translocation-induced immune activation.
Collapse
Affiliation(s)
- Nichole R. Klatt
- Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD USA
| | | | - Carol L. Vinton
- Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD USA
| | - Hannah Sung
- Department of Medicine, Pathology and Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH USA
| | - Judith A. Briant
- Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD USA
| | - Brian Tabb
- AIDS and Cancer Virus Program, SAIC Inc., NCI, Frederick, MD USA
| | - David Morcock
- AIDS and Cancer Virus Program, SAIC Inc., NCI, Frederick, MD USA
| | - John W. McGinty
- Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD USA
| | | | | | | | - Alan D. Levine
- Department of Medicine, Pathology and Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH USA
| | - Jacob D. Estes
- AIDS and Cancer Virus Program, SAIC Inc., NCI, Frederick, MD USA
| | | |
Collapse
|